Skip to main content
. Author manuscript; available in PMC: 2013 Mar 30.
Published in final edited form as: Cell. 2012 Mar 30;149(1):146–158. doi: 10.1016/j.cell.2012.02.042

Figure 6. Lrig1-CreERT2/+;Apcflox/+ mice develop colonic tumors.

Figure 6

(A) Schematic depiction of experimental design. Mice were injected with tamoxifen daily for three days, monitored by colonoscopy starting at day 50 and sacrificed 100 days post-tamoxifen induction. (B-C) Examination of mice three months post-induction revealed the mice developed distal colonic tumors (shown by colonoscopy in B and by whole mount in C). (D) H&E staining of a tissue cross-section from a representative colon. Individual tumors are indicated by the asterisks. (E) Distribution and multiplicity of tumors from seven mice with the greatest number of adenomas formed in the jejunum. (F) High-grade dysplasia was present within a large tumor (black box in D). (G-I) Immunohistochemical examination of colonic tumors for Ki67 expression (brown in G), nuclear and cytosolic β-catenin (brown in H), and high-power image of a gland that contains both cytosolic- and membrane-associated β-catenin (I). (J) Immunofluorescent examination of colonic tumors for Apc expression (white); Apc expression is heterogeneous. Scale bars represent 50μm in F, 25μm in G, I and J and 75μm in H. Error bars represent s.e.m. See also Figure S6.

HHS Vulnerability Disclosure